aee-788
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2003 (NCT00118456)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
Also potent inhibitor of SRC, ABL1 and CSF1R
KDR inhibitor
Also potent inhibitor of SRC, ABL1 and CSF1R
FLT1 inhibitor
Also potent inhibitor of SRC, ABL1 and CSF1R
ERBB2 inhibitor
Also potent inhibitor of SRC, ABL1 and CSF1R
Chemistry & pharmacology
Loading structure…
SMILES
CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1- Mol. weight
- 440.6 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL587723 ↗
Also known as
- aee788
- aee788
- aee788
- aee 788
- aee-788
- aee-788
- aee-788
- aee-788
- gnf-pf-5343
- gnf-pf-5343
- nvp-aee788
- nvp-aee788
- nvp-aee788
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00116376 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2004 | Duke University, Novartis, University of California, Los Angeles, University of California, San Francisco, University of Texas at Houston |
| NCT00107237 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2003 | Novartis |
| NCT00118456 | Phase 1 | Jul 1, 2003 | Novartis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 3 | 2 | 2003 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2004 |
5 organizations
Page 1 / 1